EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast



Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast



Journal of Asthma 47(1): 76-82



We studied the relationship between body mass index (BMI) on responses to asthma therapy using a retrospective analysis of four previously reported clinical trials. Fluticasone propionate (FP)/salmeterol via Diskus 100/50 micro g twice daily and montelukast (MON) 10 mg daily were compared. BMI was classified as underweight (less than 20 kg/m2), normal (20-24.9 kg/m2), overweight (25-29.9 kg/m2), obese-1 (30-34.9 kg/m2), obese-2 (35-39.9 kg/m2), or obese-3 (at least 40 kg/m2). Outcomes assessed included forced expiratory volume in one second (FEV1), asthma symptom score, and albuterol use. FP/salmeterol produced greater improvements compared to MON in each of the asthma outcomes studied over the entire BMI range at the week-12 endpoint, with statistically significant differences noted among normal, overweight, obese-1, and obese-3 subjects. The within-treatment responses to FP/salmeterol across BMI ranges at the week-12 endpoint was statistically significantly greater in normal compared to obese-3 for FEV1 and albuterol use, and in overweight compared to the obese-3 for each outcome studied. The within-treatment comparisons of MON across BMI ranges were significant for albuterol use in normal and underweight compared to obese-3 at the week-12 endpoint. Compared to subjects with normal BMI, the onset to peak FEV1 may require longer treatment exposure in the very obese. Treatment responses to FP/salmeterol were consistently greater compared to MON and persisted at higher BMI.

(PDF emailed within 0-6 h: $19.90)

Accession: 034499031

Download citation: RISBibTeXText

PMID: 20100025

DOI: 10.3109/02770900903338494



Related references

First-line therapy with fluticasone propionate/salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone. Journal of Allergy & Clinical Immunology 109(1 Supplement): S252, January, 2002

Reduction in asthma-related exacerbations and exacerbation-related costs during initial maintenance therapy with fluticasone propionate/salmeterol combination product versus montelukast or fluticasone propionate alone. Journal of Allergy & Clinical Immunology 111(2 Abstract Supplement): S143, February, 2003

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics 22(12): 815-825, 2004

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma. Respiratory Research 8(): 67-67, 2007

Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma. Treatments in Respiratory Medicine 4(2): 129-138, 2005

Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50mug Diskus are stepped-down to fluticasone propionate, salmeterol or montelukast alone. Journal of Allergy & Clinical Immunology 113(2 Supplement): S94, February, 2004

Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs. Annals of Allergy, Asthma & Immunology 93(6): 581-588, 2004

The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Annals of Allergy, Asthma & Immunology 82(4): 383-389, 1999

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics 20(13): 909-918, 2002

Fluticasone propionate-salmeterol versus inhaled corticosteroids plus montelukast: outcomes study in pediatric patients with asthma. Journal of Asthma and Allergy 6(): 1-10, 2013

Cost-effectiveness analysis of fluticasone propionate/salmeterol combination versus montelukast in the treatment of adults with asthma. Journal of Allergy & Clinical Immunology 109(1 Supplement): S185, January, 2002

A comparison of using fluticasone propionate/salmeterol combination versus adding montelukast in asthma patients experiencing symptoms on inhaled corticosteroids. Chest 118(4 Suppl ): 85S, October, 2000

Comparative efficacy of combination of fluticasone and salmeterol; fluticasone, salmeterol and montelukast; fluticasone, salmeterol, and levocetirizine in moderate persistent asthma: A study of 120 patients. Chest 132(4): 512a-1, 2007

Asthma control with fluticasone propionate/salmeterol 100/50mug Diskus versus montelukast in patients previously receiving short-acting beta2-agonists. Journal of Allergy & Clinical Immunology 113(2 Supplement): S117, February, 2004

In patients taking fluticasone propionate/salmeterol 100/50mug Diskus for asthma, the addition of fluticasone propionate nasal spray 200mug QD to treat concomitant allergic rhinitis has a safety profile comparable to the addition of montelukast 10mg QD or placebo. Journal of Allergy & Clinical Immunology 113(2 Supplement): S202-S203, February, 2004